Reduction of Lymphedema Secondary to Breast Cancer

Status Active, not recruiting

Clinical Trial Summary

This study evaluates the reduction of lymphedema and its complications in obese women treated with a muscle training and weight loss program as well as the improvement body composition, muscle strength, quality of life and neurocognitive function, compared to a conventional treatment control group.

Clinical Trial Description

Introduction: Breast cancer is the most frequent tumour in women. Breast cancer-related lymphedema (BCRL) occurs in 10 to 36% of patients undergoing dissection and emptying of axillary nodes and between 5 and 17% undergoing sentinel node biopsy. BCRL is associated with discomfort, pain, risk of infections, disability, symptoms of depression and anxiety and worse quality of life. The prevalence of persistent lymphedema increases with the presence of obesity. Aim: In overweight or obese women with BCRL to assess whether a muscle training and weight loss program reduces lymphedema volume and its associated complications, as well as improves body composition, muscle strength, quality of life and neurocognitive function, compared to a conventional treatment control group. Methodology: Open prospective randomized trial of 2 parallel arms. Subjects: patients referred to the Rehabilitation Unit with lymphedema secondary to breast cancer and overweight or obesity. The control group will receive the usual treatment and general dietary recommendations and the intervention group will carry out a program of supervised exercise (strength and aerobic) and weight loss (based on the Mediterranean diet and with a meal replacement). The change in volume in the limb affected by lymphedema, segmental body composition and phase angle (impedance measurement), muscular strength (hand dynamometry), level of physical activity (IPAQ), dietary parameters, quality of life (FACB+4) will be assessed. Cognitive function (Memory FSRCT test), psychological symptoms (anxiety and depression by means of HADS) NS biochemical parameters (albumin, prealbumin, lipids, CRP, 25-OH vitamin D and insulin) will be analyzed. ;

Study Design

Related Conditions & MeSH terms

Lymphedema

Clinical Trial Details

NCT number	NCT04974268
Study type	Interventional
Source	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact
Status	Active, not recruiting
Phase	N/A
Start date	May 17, 2021
Completion date	May 17, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05507346` - A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema	N/A
Completed	`NCT06067880` - Surgical Intervention and Lymphatic Diseases.
Recruiting	`NCT04797390` - A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema	N/A
Completed	`NCT02676752` - Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Completed	`NCT02506530` - Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema	N/A
Completed	`NCT06323200` - Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
Completed	`NCT02253186` - Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema	N/A
Terminated	`NCT02020837` - A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema	Early Phase 1
Recruiting	`NCT01318785` - Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications	Phase 2
Enrolling by invitation	`NCT02375165` - Biomarkers for the Detection of Lymphatic Insufficiency
Completed	`NCT02308488` - Study of Prone Accelerated Breast And Nodal IMRT	N/A
Completed	`NCT01112189` - Use of Stem Cells in Lymphedema Post Mastectomy	Phase 1/Phase 2
Completed	`NCT00852930` - Low Level Laser Treatment and Breast Cancer Related Lymphedema	Phase 4
Completed	`NCT00743314` - Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer	Early Phase 1
Recruiting	`NCT06237907` - Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
Terminated	`NCT01580800` - National Breast Cancer and Lymphedema Registry
Suspended	`NCT05366699` - LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy	N/A
Completed	`NCT06249360` - Lymphatic System Reflux After Lymphatic Operation
Completed	`NCT06220903` - The Effect of Complex Decongestive Therapy in Patients With Lymphedema	N/A
Terminated	`NCT02923037` - Hatha Yoga in Breast Cancer Survivors	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Reduction of Lymphedema Secondary to Breast Cancer — EJERDIETLIF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms